Tilray Brands Inc., through its division Tilray Medical, has announced the publication of a scientific study focusing on the pharmacokinetics of THC and CBD formulations. This research provides insights into the bioavailability of different cannabinoid formulations, contributing to the understanding of medical cannabis for therapeutic treatment. The study involved twelve healthy volunteers and compared the bioavailability of Tilray's THC:CBD extract with nabiximols, revealing higher THC and CBD concentrations with the Tilray extract. No serious adverse events were reported, and the results have already been presented. The findings may have implications for clinical use of these formulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.